Kava 用于 过度觉醒与认知性失眠
A 证据 多项大型临床试验一致显示出显著的益处。基于23项研究（4项荟萃分析，1项RCT），共2,043名参与者。各研究结果不一致。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'sleepcited.com';
const params = 'ingredient\u003Dkava\u0026condition\u003Dhyperarousal\u002Dinsomnia';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
结论
基于23项研究（4项荟萃分析，1项RCT），共2,043名参与者。各研究结果不一致。
Key Study Findings
Case Reports
n=1
6 weeks
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.
Dose: None
vs: None
Outcome: acute kava dermopathy with sebaceous gland necrosis
效果: None
None
研究人群: 41-year-old Australian woman consuming kava for anxiety and insomnia
Case Reports
n=1
Open-label
Severe kava withdrawal managed with phenobarbital.
Dose: None
vs: None
Outcome: Resolution of kava withdrawal symptoms
效果: None
None
研究人群: 45-year-old man with kava and kratom withdrawal
Other
Double-blind
The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …
Dose: AB-free kava extract
vs: Placebo
Outcome: Tobacco cessation via stress/insomnia management
效果: None
None
研究人群: Adult smokers (trial protocol)
Controlled Clinical Trial
Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.
Dose: None
vs: Vehicle control
Outcome: Acute oral toxicity, antinociceptive activity
效果: None
None
研究人群: Animal model
Systematic Review
The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.
Dose: None
vs: None
Outcome: Sleep quality improvement
效果: None
None
研究人群: Insomnia patients
Review
Calm Down With Kava: What Clinicians Need to Know.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: Kava users
Key Statistics
23
研究数量
2043
受试者
↔
Mixed
A
等级
Referenced Papers
The Medical journal …
2026
The American journal …
2025
1 次引用
BMC complementary medicine …
2024
1 次引用
Journal of clinical …
2022
27 次引用
Cureus
2022
17 次引用
Natural product research
2022
3 次引用
Journal of psychosocial …
2022
2 次引用
Combinatorial chemistry & …
2021
16 次引用
Journal of clinical …
2020
17 次引用
Chemical research in …
2019
6 次引用
Natural Products from Single Plants as Sleep Aids: A Systematic Review.
Systematic Review
Journal of medicinal …
2018
19 次引用
Sleep medicine reviews
2015
152 次引用
Holistic nursing practice
2014
10 次引用
Toxicokinetics of kava.
Other
Advances in pharmacological …
2011
79 次引用
FASEB journal : …
2010
110 次引用
Journal of psychopharmacology …
2005
176 次引用
Medicine
2005
128 次引用
Psychopharmacology
2005
36 次引用
Integrative cancer therapies
2004
59 次引用
Human psychopharmacology
2003
45 次引用
Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents.
Review
General hospital psychiatry
2002
38 次引用
Phytotherapy research : …
2001
74 次引用
Human psychopharmacology
2001
52 次引用
[Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract].
Case Report
Der Hautarzt; Zeitschrift …
1996
22 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- sleep:
- 120-250 mg kavalactones/day, 1-2 hrs before bed
上限： 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | 6 weeks | Negative | 1 |
| None | -- | Positive | 1 |
| AB-free kava extract | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| not specified | -- | Positive | -- |
最佳服用时间： 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision
Safety & Side Effects
已报告的副作用
- ⚠ Drowsiness and reduced coordination
- ⚠ Hepatotoxicity (rare but serious — consult healthcare provider)
- ⚠ Skin rash (kava dermopathy) with chronic high-dose use
- ⚠ GI discomfort
已知相互作用
- ● Alcohol — increased hepatotoxicity risk and CNS depression
- ● Hepatotoxic medications (acetaminophen, statins) — additive liver stress
- ● Benzodiazepines and sedatives — additive CNS depression
- ● CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
- ● Levodopa and dopaminergic drugs — kava may reduce efficacy
可耐受最高摄入量： 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Kava help with 过度觉醒与认知性失眠?
Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support 过度觉醒与认知性失眠 management. Our evidence grade is A (Strong Evidence).
How much Kava should I take for 过度觉醒与认知性失眠?
Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Kava?
Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Kava and 过度觉醒与认知性失眠?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.
Related Evidence
其他成分用于 过度觉醒与认知性失眠
Kava 用于其他健康状况
References
- [1] Ali Abid et al.. Med J Aust. 2026. Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption. doi:10.5694/mja2.70120 PubMed
- [2] William Bleifuss et al.. Am J Emerg Med. 2025. Severe kava withdrawal managed with phenobarbital. doi:10.1016/j.ajem.2025.06.016 PubMed
- [3] Chengguo Xing et al.. BMC Complement Med Ther. 2024. The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and insomnia: study protocol for a … doi:10.1186/s12906-024-04722-9 PubMed
- [4] Rita B Soares et al.. J Clin Med. 2022. An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. doi:10.3390/jcm11144039 PubMed
- [5] Kanika Verma et al.. Cureus. 2022. The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review. doi:10.7759/cureus.28425 PubMed
- [6] Juliana Veloso Ferreira et al.. Nat Prod Res. 2022. Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain. doi:10.1080/14786419.2021.1973459 PubMed
- [7] Deana Goldin et al.. J Psychosoc Nurs Ment Health Serv. 2022. Calm Down With Kava: What Clinicians Need to Know. doi:10.3928/02793695-20220523-02 PubMed
- [8] Ruhi Ali et al.. Comb Chem High Throughput Screen. 2021. Nutraceuticals for Sleep Disorders. doi:10.2174/1386207324666210121111446 PubMed
- [9] Jennifer L Martin et al.. J Clin Sleep Med. 2020. The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … doi:10.5664/jcsm.8486 PubMed
- [10] Pengcheng Wang et al.. Chem Res Toxicol. 2019. Enzymes and Pathways of Kavain Bioactivation and Biotransformation. doi:10.1021/acs.chemrestox.9b00098 PubMed
- [11] Jungyoon Kim et al.. J Med Food. 2018. Natural Products from Single Plants as Sleep Aids: A Systematic Review. doi:10.1089/jmf.2017.4064 PubMed
- [12] Matthew J Leach et al.. Sleep Med Rev. 2015. Herbal medicine for insomnia: A systematic review and meta-analysis. doi:10.1016/j.smrv.2014.12.003 PubMed
- [13] Stephanie Maxine Ross. Holist Nurs Pract. 2014. Psychophytomedicine: an overview of clinical efficacy and phytopharmacology for treatment of depression, anxiety and insomnia. doi:10.1097/HNP.0000000000000040 PubMed
- [14] Anthony Rowe et al.. Adv Pharmacol Sci. 2011. Toxicokinetics of kava. doi:10.1155/2011/326724 PubMed
- [15] Ping Zhou et al.. FASEB J. 2010. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. doi:10.1096/fj.10-163311 PubMed
- [16] David Wheatley. J Psychopharmacol. 2005. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. doi:10.1177/0269881105053309 PubMed
- [17] Bradly P Jacobs et al.. Medicine (Baltimore). 2005. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. doi:10.1097/01.md.0000172299.72364.95 PubMed
- [18] Kazuaki Shinomiya et al.. Psychopharmacology (Berl). 2005. Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. doi:10.1007/s00213-005-2196-4 PubMed
- [19] Keith I Block et al.. Integr Cancer Ther. 2004. Safety and efficacy of herbal sedatives in cancer care. doi:10.1177/1534735404265003 PubMed
- [20] Sheree Cairney et al.. Hum Psychopharmacol. 2003. Saccade and cognitive impairment associated with kava intoxication. doi:10.1002/hup.532 PubMed
- [21] Ka Fai Chung et al.. Gen Hosp Psychiatry. 2002. Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents. doi:10.1016/s0163-8343(02)00210-4 PubMed
- [22] D Wheatley. Phytother Res. 2001. Kava and valerian in the treatment of stress-induced insomnia. doi:10.1002/ptr.840 PubMed
- [23] David Wheatley. Hum Psychopharmacol. 2001. Stress-induced insomnia treated with kava and valerian: singly and in combination. doi:10.1002/hup.299 PubMed
- [24] R Süss et al.. Hautarzt. 1996. [Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract]. doi:10.1007/s001050050451 PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。